Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EQU-001 in Healthy Volunteers
NCT05004571Phase 1Completed
- Sponsor
- Equilibre Biopharmaceuticals
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of equ-001 in focal epilepsy (4 arms), sponsored by Equilibre Biopharmaceuticals. Primary endpoints: Adverse Events Grade 2 or higher up to 19 days and Change in pupil size from low light under high-light conditions at Day 14. Started Jul 2021; status: completed.
02
Drugs
equ-001
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT05004571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004571.